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Abstract
Background: In an unprecedented rate data in the life sciences is generated and stored in many different
databases. An ever increasing part of this data is human health data and therefore falls under data protected by
legal regulations. As part of the BioMedBridges project, which created infrastructures that connect more than 10
ESFRI research infrastructures (RI), the legal and ethical prerequisites of data sharing were examined employing a
novel and pragmatic approach.
Methods: We employed concepts from computer science to create legal requirement clusters that enable legal
interoperability between databases for the areas of data protection, data security, Intellectual Property (IP) and
security of biosample data. We analysed and extracted access rules and constraints from all data providers
(databases) involved in the building of data bridges covering many of Europe’s most important databases. These
requirement clusters were applied to five usage scenarios representing the data flow in different data bridges:
Image bridge, Phenotype data bridge, Personalised medicine data bridge, Structural data bridge, and Biosample
data bridge. A matrix was built to relate the important concepts from data protection regulations (e.g. pseudonymisation,
identifyability, access control, consent management) with the results of the requirement clusters. An interactive user
interface for querying the matrix for requirements necessary for compliant data sharing was created.
Results: To guide researchers without the need for legal expert knowledge through legal requirements, an interactive
tool, the Legal Assessment Tool (LAT), was developed. LAT provides researchers interactively with a selection process to
characterise the involved types of data and databases and provides suitable requirements and recommendations for
concrete data access and sharing situations. The results provided by LAT are based on an analysis of the data access and
sharing conditions for different kinds of data of major databases in Europe.
Conclusions: Data sharing for research purposes must be opened for human health data and LAT is one of the means to
achieve this aim. In summary, LAT provides requirements in an interactive way for compliant data access and sharing with
appropriate safeguards, restrictions and responsibilities by introducing a culture of responsibility and data governance
when dealing with human data.
* Correspondence: kuchinkw@uni-duesseldorf.de
1Heinrich-Heine-University, Düsseldorf, Germany
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kuchinke et al. BMC Medical Informatics and Decision Making  (2016) 16:81 
DOI 10.1186/s12911-016-0325-0
Background
Medical research data makes up an increasing part of
data sharing in the life sciences
In the life sciences an increasing part of stored data is
medical data derived from humans. Researchers must ef-
fectively access and link this expanding volume of hu-
man data stored in various databases, repositories, and
patient registries, in ways that make them available for
analysis while protecting privacy and the legitimate
interests of patients as well as data providers. We distin-
guish between data protection (privacy and confidential-
ity) and data security (protection against attacks,
damage and unauthorised access). In our model for the
process of data sharing as part of data bridges we con-
sider two main roles: data provider and data consumer.
The data provider is a database that offers services like
data access and download of data. In case of the involve-
ment of personal and sensitive data, the data provider
becomes a data controller conformable to the European
Data Protection Directive [1]. The researcher who used
the data provided by the database for a well-defined re-
search purpose is the data consumer. When the re-
searcher builds-up an own database and gives access to
his data he becomes a data provider. Several approaches
for protecting human data have been suggested ranging
from the creation of a political framework in the form of
resolutions or treaties, and operational guidelines for
data sharing in public health [2], to proposals for na-
tional privacy protection frameworks. These frameworks
include concepts like legitimate public health purpose,
minimum information necessary, privacy and security
standards, data use agreements [3], ethical codes like the
IMIA (International Medical Informatics Association)
Code of Ethics for Health Information Professionals [4]
and AMIA’s (American Medical Informatics Association)
Code of Professional and Ethical Conduct [5], special
guidance for genetic / genomic data covering recent
controversies around their complete de-identifiability,
and potential privacy risks originating from unintended
uses [6]. Additional approaches exist, like the human
rights-based approach to an international code of con-
duct for genomic and clinical data sharing [7], recom-
mendations how open clinical databases can be adopted
to strengthen privacy protections [8], and the iDASH
(integrating Data for Analysis, Anonymization, and Shar-
ing) Healthcare Privacy Protection Challenge that apply
differentially-private methods [9, 10].
Building data bridges between research infrastructures (RIs)
BioMedBridges [11] is a project that connects more than
10 ESFRI (European Strategy Forum on Research Infra-
structures) research infrastructures (RIs) (e.g. ELIXIR,
BBMRI (Biobanking and BioMolecular resources Re-
search Infrastructure), EATRIS (European Advanced
Translational Research Infrastructure in Medicine),
ECRIN (European Clinical Research Infrastructures Net-
work), Infrafrontier (Mouse Disease Models)) [12] to
create so-called data bridges enabling data exchange and
collaborative data sharing. Although, most data ex-
change in RIs consists of sharing animal data, collabor-
ation between RIs is increasingly based on the
integration of heterogeneous data sources that contain
human health data. Thus the researcher is increasingly
confronted with the above mentioned challenges of data
and privacy protection and the understanding of the cor-
responding legal concepts. To examine the situation of
data sharing of human health data for all BioMedBridges
member research infrastructures, a survey was con-
ducted at the beginning of the project [13]. We distin-
guished between the roles of data producer (an
individual or group that generates data and uploads the
data to a database), data provider (the database that
stores the data and provides access to its data) and the
data consumer (an individual or group that receives data
in the form of a collection to use it for query, analysis,
and reporting) [14]. The answers showed that about
36 % of the research institutions that constitute BioMed-
Bridges members provided human data in their data-
bases or imported human data and that about 79 % of
the members are data consumers using human data or
metadata for their research activities. This result indicates
that there seems to be a trend in biomedical research to-
wards an increased use of human data and therefore, it is
safe to expect that more and more databases will include
human data and that for research more and more human
health data will be exchanged in future [15].
Need for open access and legally interoperable data
sharing
RIs are complex, international infrastructures consisting
of member institutions maintaining databases and acting
as data providers and data consumers. As data owners,
nearly all RIs are employing their own data protection
measures and possess a legal framework that forms the
basis of access and data usage rules [16, 17]. But with
the BioMedBridges project that connects ESFRI RIs data
sharing will go beyond the capacities of individual infra-
structures to ensure efficient and comprehensive inte-
gration of data and data services across different RIs and
different research domains. Thus, the development of
data bridges has led to additional needs for legally inter-
operable data sharing [18]. Moreover, RIs are supposed
to create a new research environment in which re-
searchers can make use of shared access to data, data
services, and computing facilities regardless of the type
of data involved and their location. For such a new re-
search environment issues of data protection and data
governance must be addressed.
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But the heterogeneity of policies for data access be-
tween different data providers and the lack of national
harmonized legislations in Europe have increased the
relevance of legal interoperability as a key aspect of re-
search collaboration [18, 19]. Researchers are confronted
with the question, whether, on what basis and with what
limitations, human data can be used freely and made
available to support open research and open science.
Human data combined from multiple sources with
different usage restrictions and rules may result in
combined datasets that inherit the restrictions and
usage rules imposed by each source. In such cases,
the most restrictive usage rights from any of the
sources may apply. Because of the higher identifica-
tion risk of the combined data sets stronger restric-
tions for using combined datasets than the most
restrictive rights from any of the sources alone may
in some cases be necessary.
The research community in general and BioMed-
Bridges in particular want to support approaches and
methods for open data and open science [19, 20]. In
view of the mentioned challenges and restrictions associ-
ated with the processing of human health data, we
searched for ways to present researchers who access da-
tabases, share or link data, with the requirements for le-
gally compliant data sharing with as little restriction on
research and as little legal pre-knowledge as possible.
We developed an integrated approach that considers
data protection as well as data ownership (IP and li-
cences) and that focuses primarily on the requirements
for legally compliant data sharing. In order to employ a
pragmatic approach that bypasses the intricacy of legal
discussions we turned to methods of IT requirements
engineering and applied concepts of requirements engin-
eering to legal problems to create legal requirements
clusters. Requirements engineering is the systematic
process of developing requirements and traditionally,
it represents the first phase of the software life cycle
in which the functional and non-functional require-
ments to be met by the system are elicited and docu-
mented [21]. Because scenarios have been advocated
as efficient means of improving requirements engin-
eering [22, 23], we used scenarios of different data
bridges to elicit requirements. Usage scenario descrip-
tions of data bridges formed our basis for the devel-
opment of requirement clusters for data protection,
data security, intellectual property (IP), biosamples
and animal protection. These requirement clusters de-
fine conditions under which the diverse data bridges
can be used conformant with regulations and rules.
These rules and regulations for access, processing and
transfer of human data were collected, listed, and
interpreted. Finally, we developed an interactive tool
to query the developed knowledge base.
Methods
Analysis of the legal landscape for data sharing
We implemented a novel approach by using concepts
derived from computer science, especially from require-
ments engineering, which were adapted to define and
collect legal requirements for the design of data bridges.
In this context, we defined “legal interoperability” as an
extension of the general interoperability concept for di-
verse systems that forms conditions where diverse rules
sets allow the exchange of data between them. We con-
ceptualised the planned data bridges as “interfaces” be-
tween data sources for such data sharing. A “legal
interface” [24] is characterized by “requirement clusters”
defining applicable rules, roles and policies used by data-
base owners (data controllers) and acting as a kind of fil-
ter between different data sources to allow for compliant
data transfer (Fig. 1).
As a first step to understand the underlying basis of all
data access and processing rules, the legal landscape for
data exchange for research purposes was analysed, and it
became very soon clear, that it would be impossible to
cover all legal details from every European country in-
volved in the data bridges. Thus we decided to focus on
the European data protection framework consisting of
EU Data Protection Directive (Directive 95/46/EC) [25],
and Good Clinical Practice (GCP) [26] with regard to
data protection and the WIPO (World Intellectual Prop-
erty Organization) framework [27] with regard to intel-
lectual property / license rights.
In the next step, access and usage rules of important
biomedical databases (e.g. Amigo, ChEMBL (chemical
database of bioactive molecules with drug-like properties),
Ensemble, Gene Bank, European Genome-phenome
Archive) were evaluated to determine their conditions of
use, any restrictions, the existence of licenses, the role of
the data controller and possible involvements of data pro-
tection committees or similar boards. These rules were
compared with applicable legal regulations. Because we
interpreted data bridges as interfaces that allow transitions
of data flows between data providers with different "pol-
icies" and “data use agreements”, combinations of all
employed data sharing conditions and requirements be-
tween involved databases were analysed including the re-
quirements for data sharing by all data providers of our
usage scenarios (Fig. 1). Though, this covers nearly all da-
tabases with a high number of users, many minor and per-
ipheral databases, though important for a specific research
field, were not considered.
At first we attempted to use an ontology to represent
the applicable access rules and privacy requirements for
data sharing. Semantic technologies are used to address
many challenges relating to privacy and data protection,
even providing the basis for reasoning over domain
knowledge for decision support in the area of privacy
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compliance [28]. Nonetheless, in our experience, ontol-
ogies are still not suitable to represent the complexity
and intricacy associated with many of the rules and
combination of rules we encountered. We had to take
another road by employing concepts from requirements
engineering.
Usage scenarios were used as basis for the creation of
legal requirement clusters
Our approach of integrating domain experts of the use
cases to develop the usage scenarios guaranteed effective
requirements elicitation on the basis of the actual char-
acteristics of the data sources and the kind of data pro-
cessing involved in different data bridges. Usage
scenarios that represent different data bridges were cre-
ated by developing data flow descriptions for the Image
data bridge, Phenotype bridge, Personalised medicine
data bridge, Structural data bridge, and Biosamples data
bridge (Table 1). We created data sharing scenarios be-
cause scenarios as a technique are increasingly used as a
requirements discovery tool. A requirements scenario is
a simulation of what happens within the boundaries of a
specific scene for the purpose of discovering business
requirements [23]. A more formal and restricted repre-
sentation of a scenario is the use case. A use case de-
scribes a scenario as interactions between an actor and a
system and describes requirements, preconditions, trig-
gers, activities, etc. We used the term "usage scenario"
because our scenarios describe processes as well as re-
quirements for the sharing of data between RIs and we
used terminologies suitable for this activity (e.g. actor,
databases, legal requirements, access type). By using use
cases instead of scenarios we would have been restricted
to descriptions where always the user is outside the sys-
tem and the system central, a description useful for soft-
ware development, but less for legal requirement
clusters. For all five usage scenarios data sources (data-
bases), involved actors (e.g. investigators performing
analysis, bioinformaticians, data source owners, owner
of mouse line) and requirements/prerequisites for the
corresponding data bridge (requirements for the
provision and sharing of data) were collected. In
addition, descriptions of data exchange processes, events
and actions (data access and processing procedures asso-
ciated with the data bridges), and involved data types
and data standards were addressed. For each data
Fig. 1 Creation of the Requirements Matrix. Extracted rules and policies, data types used and combinations of access rules and the results of the
analysis went into the creation of the matrix. Using tabulation the matrix was created, whereby the requirements are listed as rows and the
columns represent data characteristics and applicable rules (e.g. data subject, data type, data protection (identifying, pseudonymous, anonymous),
purpose of data processing, legal approval / consent, etc. The values of the different cells contain the extracted rules for certain data types and
for certain combinations of data types and their possible combinations
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provider, the available data types, descriptions of the
mode of access (open, open restricted, restricted), data
standards, as well as the linking of databases (what data
are linked or aggregated and how is the linking done,
e.g. through phenotypic annotations) and the transfer of
data (for a specific data provider, what types of data and
metadata are transferred) were gathered. The scenarios
are completed by descriptions of the added value of the
created data bridge. In principle, our usage scenarios
served as context for the specification of the legal and
ethical requirements [29]. In several iterative rounds of
discussions and revisions, data flows and data processing
procedures in all five usage scenarios were analysed for
applicable regulations and rules. We were supported by
members of the different BioMedBridges use case
groups. Finally, the results were reviewed by internal re-
viewers and by legal experts.
All requirements were screened against descriptions of
the usage scenarios to verify the results (Fig. 1). In all
cases during the screening process, the most important
criteria for the application of the requirements turned
out to be the differentiation between human and non-
human data. In addition, the location of the data pro-
vider and the type of data to be provided played key
roles. In our scenarios the data provider is one of the da-
tabases in a research infrastructure that offers services
like the download of data to a researcher. In case per-
sonal data is involved in this data sharing national data
protection regulations may apply and the location of the
data provider has to be considered. Though, the location
of the data object, the human source of the research
data, is also of importance for compliant sharing of per-
sonal and sensitive data, consideration of the rights of
the data object belongs to the role of the data provider
and is integrated in his rules and policies.
Based on the extracted requirements, eight tables were
created containing structured descriptions of data pro-
tection requirements: Requirements for animal data and
human data, potential identification risk for human
research subjects, pseudonymous human data, anonym-
ous human data, requirements for getting access to
data/biosamples, requirements for linking and sharing
restricted access data and open access data, IP require-
ments, and requirements concerning the security of bio-
samples (Table 2). The requirements for animal data
were not further pursued, since they raise no data pro-
tection issues. The created requirement clusters define
conditions under which different data access and data
sharing activities can be used conformant with regula-
tions and rules. All requirements are based on the as-
sumption that all data providers employ rules and
policies that are compliant with the relevant national
and European laws and regulations.
In the next step, the extracted requirements and rules
of the requirement clusters form the core of a single re-
quirement matrix.
Evaluation of the requirement clusters and creation of the
matrix
Our aim was to combine the information of the require-
ment clusters in a way that it becomes usable for re-
searchers faced with a compliance problem. The tables
of the requirement clusters are already arranged in a
way that requirements are collated to specifications and
conditions for compliant data sharing (e.g. data subject,
data type, anonymous, pseudonymous). But we needed
more specific terms to organise the multitude of require-
ments. Based on an analysis of usage scenarios and re-
quirement clusters we determined conditions when
requirements can be successfully applied and formulated
these as dimensions of the corresponding requirements.
For this purpose, different conditions of a requirement
were defined that determine when a requirement can be
employed (dimension). To define these dimensions the
most important conditions from the requirement clus-
ters, data type and data subject, were used and specified
by text data, audio data, metadata, genetic data, biosam-
ple data, and country of data source. The additional
Table 1 Five usage scenarios
Data bridge Description
Image data bridge A data bridge that facilitates the comparison of cellular phenotypes specific to individual genes with morphological
imaging data from diseased tissue specimens, from both human and mouse tissues.
Phenotype data bridge Datasets from mouse or human are collected that relate to the disease states of diabetes and / or obesity. After the
annotation of these datasets, a service allows the automatic identification of phenotype matches across mouse and
human.
Personalised medicine bridge The data bridge enables access to and integration of, often heterogeneous and dispersed, patient data to enable
better treatment decisions for individual patients by using a data analysis informatics pipeline.
Structural data bridge A data bridge connecting databases with structural data and protein interaction data. Researchers receive access to
a range of available structural techniques, such as crystallography, Nuclear Magnetic Resonance (NMR), MS or EM,
and will be presented with a comprehensive structural model.
Biosamples data bridge Researchers receive information about available sample data through the BioSamples database with the aim to set
up clinical/translational research collaborations.
The five usage scenarios representing different kinds of data bridges used to create requirement clusters and to evaluate the developed legal interfaces
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Table 2 Requirement clusters
Name of cluster Requirement tables Description
Data protection/privacy General data protection requirements applicable to data
bridges; conditions, which must be fulfilled in order to
legally process personal data.
Table 1 Requirements for animal data and
other data
Requirement in relation to:
• Deletion of personal data.
• Anonymising of personal data.
• Obtaining consent from the research subject / researcher
Table 2 Potential identification risk for human
research subjects
Requirement in relation to:
• Removing metadata
• Removing data on an image
• Altering the image
• Link between biosamples and data has to be protected.
• Identification risk has to be checked after data merging
• Re-identification risk based on genetic data.
Table 3 Pseudonymous human data Requirement in relation to:
• Obtaining informed consent from the research subject
• Checking current Informed consent.
• Right to be informed
Table 4 Anonymous human data Requirement in relation to:
• Verifying the re-identification risk
Data security Data security issues with a focus on access control; measures
to protect data from possible outsider attacks, as well as
from re-identification attempts
Table 5 Requirements for getting access to
data/biosamples
Requirement in relation to:
• Data Access Committee Approval
• Research Ethics Committee Approval
• Renew Consent
• Anonymising data
• Material Transfer Agreement
Table 6 Requirements for linking and sharing
restricted access data and open access data
Requirement in relation to:
• Different Access Tiers
• Authentication/Authorization system
• Audit trail
• Secure data transfer (e.g. via encryption)
• Approval for the use/processing of data
• Approval for redistribution/sharing
• Identifying data/personal data should be stored separately
• Limitation of use
• Removal of data
• Regular backup of database
Intellectual property and licences Prevention of the infringement of intellectual property rights
needs to be fulfilled in order to protect intellectual property
rights within data bridges
Table 7 Overview of the IP requirements cluster Requirement in relation to:
• Data and metadata encryption
• Data access agreement
• License agreement
• Limited liability statement
• Material transfer agreement
• Non-disclosure agreement
• Disposal of biological samples/material
• Removal of identifying metadata
• Temporary embargo of data sharing
• User authentication
• Data labelled as 'restricted'
• Staff awareness
Kuchinke et al. BMC Medical Informatics and Decision Making  (2016) 16:81 Page 6 of 19
dimensions Data protection (protection of data source,
protection of data sharing); Access (data source access,
data sharer access) and Ethics (purpose, consent, ap-
proval, data ownership and IP/copyright) completed the
specifications and formed an interrelated dimension tree
(Fig. 2). Requirements and dimensions were combined
in form of a matrix; for each requirement listed in a row
the corresponding dimensions (columns) obtained a
value indicating if and how the requirement applies. All
possible combinations were tested and compared with
the results of the requirement clusters. In this way speci-
fications/conditions and requirements were hard-wired.
Because of their importance specifying data protection
needs, the data subject, ethics (consent and approvals),
the country of database location and the data type were
placed in the centre of the matrix and became in a later
step the first questions in the LAT survey. The dimen-
sion “data protection source” of the matrix indicates if
data is identifiable or not; it classifies the stored data of
the data source as: anonymous, pseudonymous, or de-
identified data (Fig. 3). Two types of data access were
considered; access to the data source is open access, or
access is restricted. In addition, the type of access de-
sired by the user for his/her data with values for open
access; restricted access, authentication/registration, and
combined access were allowed.
The requirements matrix is the basis for the assess-
ment activity of the LAT. By answering the questions of
LAT, relevant dimensions are selected, which are repre-
sented as columns in the requirements matrix and are
Table 2 Requirement clusters (Continued)
Security of biosamples Security issues concerning biobanking, measures that have
to be taken to securely use and share biosamples
Table 8 Requirements concerning the security
of biosamples
Requirement in relation to:
• Delete personal/identifying data
• Renew consent
• Get specific consent
• Get broad consent
• Get Research Ethics Committee approval
• Approval from a relevant regulatory body/authority
(concerning biobank research)
• Data Access request
• Negotiate Material Transfer Agreement
• Anonymisation of data
• Approval from a relevant regulatory body/authority
responsible for data transfer
• Data Access request
• Personal and Identifying data should be stored separately
• Remove researchers’ personal data
• Ask researcher to publish personal data
Five requirement clusters were created containing eight requirement tables connecting requirements with constraints and protection measures
Fig. 2 Dimension tree of the requirements. The criteria of the dimension tree organise requirements derived from five requirement clusters
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mapped to associated requirements. In this way, expla-
nations and guidance provided by LAT are generated on
the basis of the requirement matrix; they are dynamically
loaded from the database. LAT can generate the relevant
requirements that belong to a specific selection of user
specifications. In detail, the columns serve the data pro-
tection criteria (purpose restriction, need for approval,
need for consent, form of access (open, restricted) and
kind of copyright required). The rows are the require-
ments depicted as combinations of values that are con-
nected by “and” and thereby linking specifications, like
“pseudonymisation”, “anonymization”, “identifying”, “any”,
“no” together to come up with a rule that is expressed in
the LAT as a recommendation for data sharing. Because
the matrix generates results for all kind of data including
animal, structural and human data, it creates for animal
and structural data the value for the data protection of
“no”. The matrix also considers the case that non-human
data may be associated with identifying metadata (require-
ment No. 1.1–1.3).
For example, whereas requirement No. 2.1 contains
human imaging data with identifying information at the
data source used for any purpose (including data link-
ing), requirement No. 2.7 is the same but contains hu-
man imaging data where identifying information has
been exchanged by a pseudonym. Therefore, the corre-
sponding data protection column indicates “any” as
value, representing the data protection measures (neces-
sity for pseudonymisation, anonymization, and add-
itional constraints) in the first case and “anonymous” in
the second case. The rational for this mapping is that
pseudonymous data when linked to open or other
pseudonymous data are subject to an increase in the risk
of data subject identifiability. This argumentation shows
that to some degree value judgements and interpreta-
tions are inherent in the matrix. The reason for this is
that in general legal terms and statements require inter-
pretation. Data protection acts often do not define
terms, like “anonymization”, “consent”, “re-identifica-
tion” and “research purpose”. For example, genetic data
Fig. 3 Result of the semantic testing of the requirements matrix. Part of the MS Excel sheet representing the requirement matrix is shown used
for filtering the values of the requirement dimensions. Requirements were validated by calculation from the matrix using filtering
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can cause the problem that despite comprehensive anon-
ymization the re-identification of a person may still be
possible if relevant additional knowledge exist in other
databases. On the other hand, for certain images the po-
tential risk for face recognition in 3D reconstructions
magnetic resonance imaging (MRI) exist. For building
the matrix, the definitions of terms like anonymisation,
pseudonymisation, identifiability, etc. were based on the
ones data providers are using and are transcribing into
their access and usage rules. Nonetheless, when combin-
ing different rules and policies due to data sharing or
linking of data to other data sources, we made the inher-
ent judgement that when two different rules have to be
combined, the stricter rule should apply and it should be
considered that linking of data may increase the iden-
tifiability of data subjects. In order to support legally
sound data sharing, data processing agreements and
similar documents are often needed. Contractual tem-
plates with generic texts were developed and integrated
into the LAT. These templates and text building blocks
address some major issues concerning trans-border data
sharing for research. The legal background, however, is
far from being clear and reliable; it is undergoing a
process of being established, changed and harmonized
throughout Europe. Therefore, the templates are based
on a survey of a number of European and national con-
tractual models and forms; however, these are in no way
the only possible solution but suggest certain policies
and assume certain legal opinions that seem to be cur-
rently prevailing. This situation was made clear by pro-
viding several explaining texts, such as “how to use the
tool” and “how to use the template”. In addition, some
of these texts point to major legal debates such as “Can
biosamples be anonymised?”
Technical realization of LAT
To access and query the knowledge base a user interface
was created. This user interface enables the querying of
the requirement matrix by researchers without any pre-
vious legal knowledge. The main aim was to create the
user interface as easy to use and as intuitive as possible.
By answering questions about the kind of data involved,
the user specifies conditions for applying the require-
ments (dimensions of the requirement matrix) and
obtaining the applicable requirements for a specific data
provision or sharing situation (Fig. 4). LAT provides re-
searchers with a set of requirements to pay attention to,
as well as regulations to consider, and aspects to watch
(e.g. increased risk of identifiability). In summary, LAT
gives no legal advice, but provides requirements for dif-
ferent kinds of data sharing situations to enable legally
compliant data exchange. The technical realization of
LAT employs various open source components (Table 3).
LAT has been developed as a plain html web application
containing the JavaScript frameworks AngularJS and
jQuery. Spring MVC and Hibernate frameworks were
used to realise the backend implementation.
Testing and evaluation of LAT
The complexity of the requirements matrix made it ne-
cessary to test all possible queries and assessment results
in a structured way. The assessment tool was tested on
Fig. 4 Usage of the LAT. The user answers the questions of the LAT and receives a list with relevant requirements for data access and
data sharing
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two different levels: first, semantic and logic integrity of
the requirements matrix; second, correctness of the im-
plementation (tool). To test the requirements matrix,
two test scenarios were developed: first, a non-
contradictory requirement test (it was separately tested
whether requirements that were assessed resulted in
contradictions and whether all compatible requirements
were selected); second, it was tested whether queries re-
sulted in the correct requirements. Two checkers
worked separately and exchanged their tests in order to
cross-validate their results. All tests were performed
with the help of the filter tool of MS Excel.
After completion of the matrix test, the matrix was
frozen and the tool testing was begun. It was tested if
the query workflow precludes all non-feasible selections
(Fig. 5). For this purpose, a query use case was devel-
oped and expected requirements were calculated
from the matrix by filtering (Fig. 5). Then the validated
queries were entered into the tool and the results
were compared with the expected ones. These tests
showed that the requirements matrix was implemented
correctly.
In addition, a preliminary usability testing was per-
formed. Three interviews with potential users that were
members of the BioMedBridges consortium were con-
ducted. The potential users were typical researchers,
working about personalized medicine at FIMM (Finland
Institute for Molecular Medicine) (Finland), about popu-
lation cohort studies at the THL (National Institute for
Health and Welfare) Biobank (Finland) and as a biologist
at the Institute of Experimental Genetics (Germany).
The tool could be used by all evaluators without prob-
lems. No issues with the user interface were encoun-
tered. LAT was seen as very useful for the topics of data
protection and / or ethics during data sharing. As strong
point it was mentioned that the tool is able to provide
assistance and guidance in the case of uploading of iden-
tifying data to an open access data source. It was stated
that the tool should be able to assist in the planning of
clinical studies, e.g. by simplifying the right choice of in-
formed consent for different settings. Though users had
different opinions about the guidance function of the
tool, checklist for different types of IP issues and in-
formed consents and recommendations for means for ef-
ficient data anonymisation procedures were asked for.
Meanwhile LAT has been demonstrated and evaluated
during several workshops of the BioMedBridges project.
Provision of the tool
LAT is made available under an Open Source licence
(Apache) upon request. Access to a fully functional test
version is provided [30] as well as a training website with
links to documentation [31].
Table 3 Technical components of the LAT tool
Tool Version Licence
Ubuntu 12.04.5 GNU GPL
Apache Tomcat [65] 7.0.42 Apache License 2.0
jQuery 2.1.4 MIT License
Hibernate 4.3.11 LGPL
Spring MVC 4.1.6 Apache License 2.0
AngularJS 1.4.3 MIT License
Java [66] 1.7.0.72 GPL Version 2
Components of LAT tool and contribution of Open Source Software and
their licences
Fig. 5 Course of a generic query. Shown is the workflow through the questions and decision points that characterises the user interface of LAT.
The workflow begins top left with “location of data source” and ends at the right end. Depending on the data source not all of the specifications
need to be determined/answered. Simultaneously with answering the questions, relevant results are presented (bottom lane)
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Results
Our methodological approach created rich information
about requirements for compliant data access / data
sharing by studying conditions, specifications and rela-
tions for data sharing based on actual research data
flows and databases used for research and by consider-
ing rules and regulations. Representing the core of the
knowledge base the requirement clusters are presented
in the following text in detail. Table 4 gives an overview
over the involved databases and the main access rules of
the different requirement clusters; detailed listings of the
requirements can be found in the Additional file 1: Ta-
bles S1–S5.
Requirement cluster: imaging bridge
The analysis of cell and tissue image datasets and the
linking of their associated annotations and metadata can
provide powerful predictors for biomarkers as well as for
drug targets in cancer. In this usage scenario four major
databases were considered (Table 4). Though heteroge-
neous in data content, their data protection requirements
are rather similar: MitoCheck database, Ensembl, and
ArrayExpress for cancer expression data, contain anonym-
ous human data that is stored in open access databases.
On the other hand, the Mouse Cell Line database restricts
its access.
Requirement cluster: phenotypic bridge
The Phenotypic data bridge addresses the challenge of
connecting different ontological phenotypic annotations
of mouse and human in the domains of diabetes and
obesity. This data bridge is characterised by the involve-
ment of a large number of open access databases
(Table 4): EuroPhenome / IMPC (International Mouse
Phenotyping Consortium), ArrayExpress / Gene Expres-
sion Atlas, ChEMBL, Metabolights and Reactome.
CERM (Centro di Ricerca di Risonanze Magnetiche)
data sets are defined as metabolomics data (only selected
datasets will be used) and are stored in a database with
restricted access. The datasets of the University of Graz
contain mouse and human data and are stored under re-
stricted access conditions.
Table 4 Databases and their access policies considered for the requirement clusters of data bridges
Data providers Summary of main access restrictions and policies
Requirement cluster: Imaging bridge See: Additional file 1: Table S1
Mouse tissue imaging data (Infrafrontier), Human tumour tissue
data (BBMRI/ FIMM), MitoCheck (cell-based RNAi screens),
WebMicroscope (mouse and human image data sets),
Ensembl, ArrayExpress, Phenotator, MitoCheck
Restricted access, data linking only possible, if the data provider
gives permission based on the availability of informed consents,
consent form which permits such a research may be required,
application to the steering committee or principal investigator,
Images are owned by image generator
Requirement cluster: Phenotypic bridge See: Additional file 1: Table S2
EuroPhenome, IMPC, Gene Expression Atlas (GXA), ArrayExpress,
ChEMBL, Metabolights, Reactome, CERM datasets, Biobank/BBMRI
(University of Graz, Austria)
Predominantly open access, open restricted for private data
(pre-publication/ unpublished), open access, when data is
used for research purposes, biobank with restricted access
(access rules include project application and approval committee)
Requirement cluster: Personalised Medicine bridge See: Additional file 1: Table S3
ICGC (International Cancer Genome Consortium), TCGA
(The Cancer Genome Atlas), EGA (European Genome-phenome
Archive), Cosmic (Catalogue of somatic mutations in cancer),
GEO (Gene Expression Omnibus), Array-Express, ChEMBL,
Reactome, Ensembl, Drugbank, Pharmgkb, BioSD, Biobanks (BBMRI),
EU-OPENSCREEN, ECRIN (CTIM), FIMM Institute for Molecular
Medicine Finland (EATRIS)
Open access and data with and without restricted access,
different policies apply, controlled access datasets means
access control, Data Access Compliance Office (DACO)
handles requests from scientists for access to controlled data,
requirement for user certification via Data Access Request,
download of datasets must be approved by the specified
Data Access Committee (DAC), requires users to sign a Data
Access Agreement (DAA), which details the terms and
conditions of use for each dataset, all controlled access
downloadable datasets are encrypted, restricted access
usually for pre-published/unpublished data
Requirement cluster: Structural Data bridge See: Additional file 1: Table S4
UniProt, AmiGO (Gene Ontology database), EMDB
(Electron Microscopy Data Bank), IntAct (Molecular Interaction
Database), GenBank (NCBI), ELIXIR, BMB database
All are open access
Requirement cluster: Biosample data bridge See: Additional file 1: Table S5
Mainly restricted access. Open access for aggregated
anonymised information or metadata about samples, for data
access researcher has to apply to Data Access Committee
(DAC) of biobank and has to agree to use data only for research,
which has been specified between biobank and researcher,
and not to try to identify patients
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Requirement cluster: personalised medicine bridge
Personalised medicine uses personal data sets that can
identify the corresponding data subject. Therefore, re-
search in personalised medicine needs special protection.
Anonymous data is available in published articles, and
certain databases: Cosmic, ICGC (International Cancer
Genome Consortium) (in parts open), TCGA (Cancer
Genome Atlas) (in parts open), ArrayExpress, GEO (Gene
Expression Omnibus), Drugbank, ChEMBL, Pharmgkb.
ICGC, TCGA, EGA (European Genome-phenome Arch-
ive) are databases with restricted access (Table 4). In
addition, personal data stays in the protected environment
of FIMM and is enriched by data from many different
open sources.
Requirement cluster: structural data bridge
A structural data bridge connects structural biology
datasets from e.g. mass spectrometry (MS) and electron
microscopy (EM) with specific features of biological sys-
tems, such as protein interactions. It provides links to
open databases, such as GenBank, UniProt, AmiGO,
EMDB (The Electron Microscopy Data Bank) (PDBe,
Protein Data Bank in Europe,) (Table 4). Primary experi-
mental data are stored at the INSTRUCT Centre, mostly
in a local database. The linking of data sets is based on
the availability of proper identifiers, e.g. proteins IDs.
Requirement cluster: biosample data bridge
The BioSamples (BioSD) database at EBI is becoming an
important resource for researchers to query the availabil-
ity of biological samples from a wide variety of different
biobanks. Biobanks follow their national and local regu-
lations with respect to data protection and biosample
management. Only information that can be openly
accessed in biobanks is exported to and collected by Bio-
Samples (Table 4). The access to BioSamples is open; no
sensitive information on human subjects is provided or
stored.
To ensure the simplicity of the tool, it was decided to
concentrate on the requirements of the data provider
role. This was in line with the “Ethical and Governance
Framework” of BioMedBridges [32] that states that the
data controller who is sharing/providing data is respon-
sible for clearing legal requirements on the way to mak-
ing the data available. Any constraints arising for
example from consent limitations have to be reflected in
data transfer agreements. In general, data can only be
made available to the extent that is allowed under the
local legal regime including ethics votes and patients’/
donors’ consent. Because of this simplification, LAT can
serve as a tool for data controllers, who want to get an
overview over the legal constraints before making re-
search data available to other researchers or within a re-
search project.
Development of a user-friendly interface for LAT
We wanted to create a tool that is easy to use and fast in
providing results. It should be used by the normal re-
searcher and data provider, without having to resort on
legal expert knowledge and the interpretation of legal
texts (Fig. 4). For this purpose, an interactive user inter-
face was created to query the knowledge base that is based
on a questionnaire (Fig. 6). Because the requirements
matrix consists of a large table with requirements as rows
and specifications/conditions, the so-called requirement
dimensions, as columns with all fields harbouring values
Fig. 6 LAT interface consists of two parts: a survey part showing a set of questions (left side) and the corresponding results part with the
assessment (right side). Because no question has yet been answered, the assessment part doesn’t show any results
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for the realisation of the requirements, the matrix
forms an easily accessible database for querying. The
LAT user interface depicts eleven questions about di-
mensions covering the type of data sources and the
kind of data to be accessed or shared to guide re-
searchers through the requirement clusters situated in
the knowledge base. The location of the data source,
the existence of human data, the kind of data and
existing access restrictions of the data to be shared or pro-
vided are specified. By answering questions by clicking on
suggested specifications, LAT initiates corresponding
queries and the user interface depicts the assessment with
recommendations to what to look at to ensure compliant
data sharing (Figs. 5 and 6).
Technically, questions about the location of data
sources, data origin (human, animal,…), kind of data, kind
of access to data, desired type of access and the subject to
copyright / intellectual properties are mandatory and lead
to certain decision points (Fig. 5). Depending on the kind
of databases accessed and the linking and processing of
data planned, LAT responds to the answered questions,
by offering different, new questions to be answered,
thereby altering the workflow at the corresponding six de-
cision points (Fig. 5 and 7). Simultaneously, with the
choice of specifications, relevant results are presented on
the same page. These results consist of legal and ethical
requirements and recommendations that are specific for
the selected kind of data and database (Fig. 8). The user
interface provides supplementary online assistance in
form of texts, like Q&A (Questions and Answers) and
tool tips.
Depending on the given answers, conditional new
questions may be presented (Fig. 7). Therefore, at the
beginning of a query not all questions are shown and de-
pending on the questions answered not every question
possible may be shown to the user. For example, the se-
lection of “HUMAN” as fundamental type of data trig-
gers the display of an additional question about the kind
of human data to be shared, a question allowing a more
detailed selection between identifying data, pseudonym-
ous data or anonymous data.
By answering questions and selecting specifications,
the assessment part of the user interface is activated and
presents results of the assessment as a list of require-
ments (Fig. 8). These results are specific for every given
answer and give a direct output of necessary require-
ments as applicable rules and regulations for the specific
data sharing case selected in the survey part. The results
are presented as listing of requirements for compliant
data sharing, covering data protection / privacy protec-
tion, data security, IP, biosample data security and
additional information, like for example, the provision
of sample texts for Data Transfer Agreements or Pro-
vider Agreements. Figure 8 shows an example of the
sharing of human data with a restricted access data-
base, where the assessment indicates that the require-
ments for the “right to know” of the data subject as
well as the positive vote of a “Data Access Committee”
may be needed. In addition, biosample data should be
pseudonymised.
Templates for Data Transfer Agreements and Pro-
vider Agreements are available through the link
Fig. 7 Conditional questions. Conditional questions depending on given answers. The example “HUMAN” data is shown. The right side shows the
new, conditional questions
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Fig. 8 (See legend on next page.)
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“EXPLANATIONS”. As additional help for the user,
next to the requirements in the results list, the cor-
responding regulations that form the basis for these
requirements are shown. Links exists to supplemental
texts explaining associated legal regulations.
Discussion
When dealing with provision or sharing of human data,
researchers are confronted with a lack of uniformity of
legal requirements and differences in the use of legal ter-
minologies. Different types of data usage licenses and
additional restrictions on data sharing, like the process-
ing of data only for non-commercial purposes, may
apply. This complicated situation may discourage
researchers to include human data to answer their re-
search questions. Thus, the LAT was designed to pro-
vide researchers in an understandable and non-expert
way with the basic requirements for their data access
and sharing needs. We have collected and analysed data
access rules, data usage rules and data provider policies
of many of the leading European databases in the life
sciences and extracted requirements from them. And we
employed an approach originating from requirements
engineering in the IT domain to the legal domain of data
protection rules. Until now the legal domain is still con-
fronted with problems to translate the legal logic embed-
ded in texts of laws and regulations into machine
readable rules; although some groups claim to be near to
this aim [33–37]. Our first idea was therefore to use
legal ontologies to transform legal rules into a machine-
readable form. Several legal ontologies were analysed
with respect to data protection, confidentiality, and in-
tellectual property for usage in LAT. For example, the
NEURONA ontology [38] is an application-oriented
ontology and model for the knowledge necessary for the
development of data protection compliance applications
covering the correct use of security measures for
personal data. OntoPrivacy [39] is a modification of a
glossary of keywords from the Italian personal data pro-
tection code to support search and allow retrieval and
visualization. The LRI-Core Ontology (Ontology of Fun-
damental Legal Concepts) [40] covers main concepts
that are common to all legal domains. None of these on-
tologies was useful for us, though, because none covers
data sharing for research purposes and none could cover
the logical intricacies associated with different forms of
informed consent and different definitions of anonymity.
As mentioned above, the diversity and complexity of the
rules governing data protection in Europe results in the
need to abstract from these complex rules. Privacy re-
quirements are the obligations that must be fulfilled for
a compliant sharing and processing of sensitive patient
data and this covers policies for consent, anonymity, and
the right of the data subject to be informed. Such data
protection policies play a major part in user specific
privacy protection for service-oriented architectures
[41]. In this architecture, privacy services (PS) are used
in combination with privacy policies to create privacy
contracts that outline what is allowed or not allowed
with identifiable information. This approach will play an
important role for service-oriented research applications.
Another way is to employ ontology-based privacy com-
pliances [41, 42]. The modeling of high-level policies de-
rived from European and national data protection laws
can create privacy-aware access control policies by using
semantic Web technologies [43, 44]. But in the complex
legal domain, the modeling of legal relationships cannot
be expressed in OWL alone, because the logic of legal
properties is not rich enough for this purpose resulting in
the need for additional methods, like the use of the Se-
mantic Web Rule Language (SWRL).
As a consequence, we decided to go the other way;
our focus was not on the analysis and interpretation of
legal texts, but on the application of the rules the differ-
ent data providers require and provide. Our approach
was to abandon the employment of ontologies to include
semantic of legal regulations in our tool, but to concen-
trate on the access rules and data processing rules of
European databases and extract the most important con-
cepts in form of a dimension tree that links the data ac-
cess requirements with the ones for data sharing.
But conciseness of approach always entails a limitation
in the granularity of information and therefore, our tool
has to leave certain questions open, which can only be
resolved with the local authorities, like data protection
authorities or ethics committees. Nonetheless, the user
of LAT gets an overview over the major legal require-
ments and guidance, including the information when to
consult legal departments or local authorities. Because
the requirements matrix as a table is easily extensible, it
can be further developed into a more comprehensive
tool covering in more detail legal issues. For a data pro-
vider who offers data as a service and thus takes on the
role of a “data controller” the recommendations LAT
produces for compliant data sharing can be the first step
and must be completed by consideration of relevant
(See figure on previous page.)
Fig. 8 Exemplary assessment results. Only details of the lists of results for IP, Biosamples, Data protection, Data security and additional information
are displayed. The upper parts of "Intellectual Property", "Data Security" and "Additional Information" are shown. The lower edges have triangulars
to indicate that for the above mentioned topics more information is provided, but not shown in the figure. ID = requirement number. By clicking
on the “Explanation” button, the user is linked to the respective regulations, or associated document templates, like Data Transfer Agreements
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local laws and regulations. Until now LAT considers only
the EU framework and UK regulations. Such a comple-
mentation of LAT with national regulations is in agree-
ment with the legal framework of RIs, for example with
the principle of employing local regulations called
“Home State Compliance” by BBMRI. Under this
principle, each BBMRI member has to secure and guaran-
tee that operations within the research infrastructure, es-
pecially the cross-border transfer of data and biosamples,
are compliant with the member's own national laws [45].
As mentioned above, legal compliance of research with
sensitive data is of growing concern for the research
community. There exists a considerable need in the Life
Sciences for easy to apply guidance for the secure and
compliant handling of human health data. Many re-
searchers as well as experts in data protection agree that
the sharing of sensitive data needs to be planned from
the start of a research project in order to be successful
[46]. As shown in this paper, sharing research data
comes with many ethical and legal issues. Since these is-
sues are often complex, they can rarely be solved with
one size fits all solutions [46]. In general, the complete
anonymization of research data before any sharing
process is in general being recommended; but often this
is not possible. Especially for data, which cannot be
anonymised, strict governance procedures as part of a
data protection framework to restrict data access and
usage, is needed. Many groups have developed some
form of guidance to tackle these problems. To help to
design and implement data governance structures in-
cluding the ones for encryption, identity management,
safe havens, data brokers, etc., a zone model consisting
of three privacy protection zones (Care Zone, Non-Care
Zone and Research Zone) provides a graphic reference
system to help design privacy frameworks [47]. In
addition, access may be based on explicit consent (with
an option to agree or disagree with the collection, pro-
cessing, or disclosure of personal information) or on
country-specific or local regulations (e.g., exemptions to
consent for research) usually allowing for an opt-out re-
gime. In this context, funder organisations, universities
and research infrastructures have developed guidelines
how to deal with sharing of research data including sen-
sitive data for research, for example University of Cali-
fornia, ANDS (Australian National Data Service), UCL
(University College London), BBMRI, ECRIN, Wellcome
Trust [48–53]. For example, the Regulatory Affairs Data-
base of ECRIN [53] provides advice to people who want
to plan mono- or multi-centre clinical trials within dif-
ferent European countries including links to legal docu-
ments and the contact addresses of national authorities
of 15 European countries. In addition, ELSI (Ethical,
Legal and Social Issues) sources provide information
about the requirements for using and sharing genetic
human data. ELSI2.0 aims to encourage international
collaboration and discussion around the Ethical, Legal
and Social Implications of research in the Life Sciences
[54]. HumGen is an international database on ethical,
legal and social issues in human genetics including a
database of laws and policies [55]; BioPolicy is a Wiki
guide to laws and policies governing the use of human
genetic and reproductive technologies [56]; ELSI Genet-
ics Resource Directory (ELSI ReD) has been developed
to provide a source to locate documents on genetic test-
ing and screening, pharmacogenomics, genetic patents,
genetic databanks and gene therapy with the focus on
ethical and legal issues raised by the international trans-
fer of data and results [57]. The U.S. Department of En-
ergy (DOE) and National Institutes of Health (NIH)
support a large bioethics program [58] and The Center
for Transdisciplinary ELSI Research in Translational
Genomics (CT2G) brings together different resources
and serves as a repository for ethical, legal and social
analysis of translational genomics [59].
For our analysis we focused on four resources that
offer some kind of interactive user access to their docu-
ments: on P3G-IPAC (International Policy interoperabil-
ity and data Access Clearinghouse) Generic Clauses
Database [60], BBMRI Legal WIKI [61], Human Sample
Exchange Regulation Navigator (hSERN) [62] and Treat-
NMD (Translational Research in Europe for the Assess-
ment and Treatment of Neuromuscular Disease) Regula-
tory Affairs Database [53].
The International Policy interoperability and data Ac-
cess Clearinghouse (IPAC) [60] provides services for pol-
icy interoperability and access authorization. On the
other hand, the BBMRI Legal WIKI [61] offers templates
for European biobanking research, like standard personal
data processing security agreements and material trans-
fer policies. hSERN [62] provides information on theor-
etical and practical legal aspects for exchanging
biosamples across borders. All these sources, more or
less, provide the user with general legal information,
links to the relevant acts and ordinances and may even
provide templates for documents like data sharing agree-
ments. At the first sight helpful, such resources may bur-
den most researchers with the need to study and
interpret legal documents. Thus, in our opinion, the
mentioned lists of national regulations offer little help
for the concerned researcher, because one cannot expect
that a researcher for each data sharing problem consults
a list of regulations and reads through all legal texts. In
contrast, our approach focuses on data access and usage
rules employed by various data providers and treats
them as requirements for the data sharing processes.
This approach is possible, because all data providers are
subordinate to the corresponding national rules and reg-
ulations and responsible that at their database data
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protection for sensitive human data is enforced and con-
sequently, they have already done their work and read
and interpreted the relevant legal texts.
This request for simplicity was mirrored in the recep-
tion of the tool by the BioMedBridges community. The
usability of the tool was evaluated by interviews and
hands-on test sessions with potential users at several
BioMedBridges project meetings. The researchers com-
ing from diverse research areas, like mouse phenotypic
research, cancer research, personalised medicine, com-
mented on the tool during testing. These comments
were used to improve the user interface. In summary,
the tool was judged by researchers to be very useful con-
cerning data protection and/or ethical issues and espe-
cially the support in the form of guidance in the case of
uploading of potentially identifying data to an open ac-
cess data source was appreciated [63]. In addition, dur-
ing several telephone conferences with BioMedBridges
members and experts, the usability of LAT was further
improved, with the aim to make the use as easy as pos-
sible and to show results of the selection of criteria as
immediate as possible. Sections for "How to use this
tool" and "Frequently Asked Questions" were added,
explaining each query question of the tool and com-
menting on specific issues, for example: "Is there a legal
basis to share the data or biosamples without specific
consent?" While researchers were largely positive, some
even enthusiastic about the tool, for many legal experts
and data security specialists the tool was too simplistic
and the direct consideration of legal texts on European
and national levels was missed. The positive feedback
from researchers encouraged us to continue in the direc-
tion of creating a simple tool usable without legal know-
ledge, but also to think about extending the tool to
include more local and national regulations, a further
development that is much more demanding and will
have to involve the contributions of many legal experts
from different countries. To support this approach,
BBMRI with its Common Service ELSI consisting of
legal experts from its RI member countries offered to
adopt the tool and to integrate it with other tools such
as hSERN and the BBMRI Legal WIKI.
Nonetheless, LAT is a proof-of-concept application
and still has some shortcomings. But before implement-
ing further improvements, attention should be taken not
to abandon the simplicity and easy usability that charac-
terises LAT. Finally, it should be stressed that LAT is
not intended to provide legal counselling, but acts on a
level higher; a level where legal text is already inter-
preted and presented as rules and recommendations.
Conclusions
It cannot be the responsibility of the researcher who
wants to access data to handle the legal intricacies of EU
and national data protection legislations; this must be
done by the data provider who acts as a data controller
and who is the only one, who can check, whether any
intended data sharing is compliant with his local laws in-
cluding ethics committees votes and patients’/donors’
consent. The data controller must respect a set of rules
as set out, for example, in the Data Protection Directive
[64], like that personal data is processed legally and
fairly, the data is collected for explicit and legitimate
purposes and used accordingly and the data collection is
adequate, relevant and not excessive in relation to the
purposes. To this effect, LAT builds on this obligation
and assumes that the corresponding data controller has
respected them. Nonetheless, BioMedBridge's data bridges
should contribute to a simplification and harmonization
of data sharing conditions and support open access as far
as possible. Data bridges must be opened for human
health data and LAT is one of the means to further this
aim. Here we show that our pragmatic approach to build
on the available data access and processing rules of estab-
lished databases does work and facilitates considerably the
search for compliant data sharing requirements. We could
demonstrate that IT concepts can be successfully applied
to the legal domain allowing the use of concepts like “re-
quirement cluster” and “legal interface” as part of data
sharing between different data providers and data con-
sumers. For the researcher querying the tool the provided
information is for the most part sufficient and complete.
This is based on our pragmatic approach to consider the
data sharing rules of all data providers in BioMedBridges
and all possible combinations between them. Nonetheless,
gaps are present, not all rules are linked to source legal
documents, and neither national legal peculiarities (with
the exception of United Kingdom, UK) nor different forms
of informed consent and committee approvals are consid-
ered. In addition, a more specific questionnaire and the
generation of more specific response information would
improve its usefulness for researchers. Nonetheless, LAT
is a first step to deal with legal requirements in an inter-
active way. It is one of its achievements that by providing
requirements for compliant data access and sharing with
appropriate safeguards, restrictions and responsibilities, it
is introducing a culture of responsibility and data govern-
ance when dealing with human data, and even with non-
human data.
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